Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;76(1):59-70.
doi: 10.1111/all.14547. Epub 2020 Sep 7.

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

Ioana Agache  1 , Claudio Rocha  2 , Ana Pereira  2 , Yang Song  2 , Pablo Alonso-Coello  2   3   4 , Ivan Solà  2 , Jessica Beltran  2 , Margarita Posso  3 , Cezmi A Akdis  5   6 , Mubeccel Akdis  5   6 , Knut Brockow  7 , Tomas Chivato  8 , Stefano Del Giacco  9 , Thomas Eiwegger  10   11   12 , Kilian Eyerich  13 , Ana Giménez-Arnau  14 , Jan Gutermuth  15 , Emma Guttman-Yassky  16 , Marcus Maurer  17 , Graham Ogg  18 , Peck Ong  19 , Liam O'Mahony  20 , Jürgen Schwarze  21 , Thomas Werfel  22 , Carlos Canelo-Aybar  2   3   4 , Oscar Palomares  23 , Marek Jutel  24   25
Affiliations

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

Ioana Agache et al. Allergy. 2021 Jan.

Abstract

This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU). PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CSU-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Ten RCTs including 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated. Omalizumab 150 mg does not result in clinically meaningful improvement (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) -5; 95%CI -7.75 to -2.25), and the itch severity score (ISS)7 (MD -2.15; 95% CI -3.2 to -1.1) does not increase (moderate certainty) quality of life (QoL) (Dermatology Life Quality Index (DLQI); MD -2.01; 95%CI -3.22 to -0.81) and decreases (moderate certainty) rescue medication use (MD -1.68; 95%CI -2.95 to -0.4). Omalizumab 300 mg results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD -11.05; 95%CI -12.87 to -9.24), the ISS7 (MD -4.45; 95%CI -5.39 to -3.51), and QoL (high certainty) (DLQI; MD -4.03; 95% CI -5.56 to -2.5) and decreases (moderate certainty) rescue medication use (MD -2.04; 95%CI -3.19 to -0.88) and drug-related serious AEs (RR 0.77; 95%CI 0.20 to 2.91).

Keywords: chronic idiopathic urticaria; chronic spontaneous urticaria; itch severity score; omalizumab; urticaria activity score.

PubMed Disclaimer

References

REFERENCES

    1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73(7):1393-1414.
    1. Eyerich S, Metz M, Bossios A, Eyerich K. New biological treatments for asthma and skin allergies. Allergy 2020;75(3):546-560.
    1. Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 2017;72:2005-2016.
    1. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197-201.
    1. Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003;58:621-623.

Publication types